Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory
Key takeaways
- Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory Maham Fatima Wed, June 17, 2026 at 8:46 PM GMT+7 2 min read ROIV MRNA Roivant Sciences Ltd.
- In its clinical portfolio, Roivant reported positive results for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with further updates expected later this year.
- CEO Matt Gline expressed confidence in the company’s momentum, emphasizing the potential of their differentiated pipeline to address significant patient needs.
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold Territory Maham Fatima Wed, June 17, 2026 at 8:46 PM GMT+7 2 min read ROIV MRNA Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 12 Best Growth Stocks Trading in Oversold Territory. On May 20, Roivant Sciences reported its financial results for FQ4 and the full year FY2026, alongside a comprehensive business update. The company finished the year with $4.3 billion in consolidated cash and marketable securities, providing a runway into profitability. A significant highlight was a $2.25 billion global settlement reached with Moderna, concluding pending patent-infringement litigation.
In its clinical portfolio, Roivant reported positive results for IMVT-1402 in difficult-to-treat rheumatoid arthritis, with further updates expected later this year. Additionally, brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis, and its commercial launch for dermatomyositis is scheduled for late September 2026. Topline data for several other programs, including studies in non-infectious uveitis and pulmonary hypertension, are also anticipated in H2 2026.
CEO Matt Gline expressed confidence in the company’s momentum, emphasizing the potential of their differentiated pipeline to address significant patient needs. With multiple clinical readouts on the horizon and clear timelines for upcoming launches and trial results, Roivant Sciences Ltd. (NASDAQ:ROIV) maintains a strong strategic trajectory for the remainder of the calendar year.